The suit against Boston Scientific

Poor Boston Scientific. It's stumbling under billions in debt. Its $27 billion acquisition of Guidant didn't bear the expected fruits. Now, it's paying $17 million to settle a dispute with the state attorney general over flawed Guidant defibrillators, on top of the $195 million it's shelling out to settle related class-action lawsuits. And a federal judge is letting Johnson & Johnson's suit against Boston Scientific--over that very Guidant deal--go forward.

Originally, Guidant had agreed to sell out to J&J, but then Boston Scientific wooed the device maker away. J&J sued both Boston Scientific and Abbott Laboratories--which bought some pieces of Guidant--over its failed acquisition attempt. Though the judge dismissed J&J's claims against Abbott, and a few other claims against Boston Scientific, he let the breach-of-contract portion of the $5.5 billion lawsuit stand.

- here's the AP report on Boston Scientific
- and here's the report from The Wall Street Journal

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.